Tern Plc secures extension on £120,000 loan balance

TERN

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced that the repayment date of the loan facility agreement originally announced on 12 June 2023 has been extended, with the agreement of the Loan provider, to 11 September 2026.  The Board considers that the extension gives the Company greater negotiating flexibility in relation to funding the future capital requirements of its investee companies.  Since being entered into the Loan has been varied twice previously, as announced on 4 September 2024 and 15 September 2025.

The Company has agreed to make a payment of £38,432.88 to the Loan provider as a partial repayment of the outstanding Loan balance and accrued interest, plus a Loan extension fee of £6,000. Following these payments £120,000 will remain outstanding under the Loan and this amount, plus accrued interest at a rate of 1.00% per calendar month, will be repayable by the Company on or before 11 September 2026.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Search